scispace - formally typeset
S

Shaowei Li

Researcher at Xiamen University

Publications -  184
Citations -  3144

Shaowei Li is an academic researcher from Xiamen University. The author has contributed to research in topics: Epitope & Capsid. The author has an hindex of 26, co-authored 151 publications receiving 2366 citations.

Papers
More filters
Journal ArticleDOI

Prevalence, isolation, and partial sequence analysis of hepatitis E virus from domestic animals in China

TL;DR: Serum samples collected from pigs, cattle, and goats from various regions of China to determine whether they had been infected with hepatitis E virus (HEV) supported the hypothesis that sporadic hepatitis E in China is zoonotic.
Journal ArticleDOI

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

TL;DR: How the crucial quality attributes of VLP-based human vaccines against all three disease indications were assessed, controlled, and improved during bioprocessing through an array of structural and functional analyses is reviewed.
Journal ArticleDOI

Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host Interaction

TL;DR: The crystal structure of the HEV capsid protein domain E2s, a protruding domain, is reported for the first time, together with functional studies to illustrate that this domain forms a tight homodimer and that this dimerization is essential for HEV–host interactions.
Journal ArticleDOI

Virus-mimetic nanovesicles as a versatile antigen-delivery system.

TL;DR: VMVs are demonstrated to be straightforward, robust and tunable nanobiotechnology platforms for fabricating antigen delivery systems against a wide range of enveloped viruses.
Journal ArticleDOI

Structural basis for the neutralization and genotype specificity of hepatitis E virus

TL;DR: The complex crystal structure of 8C11 Fab with HEV E2s(I) domain is reported and the key residues that distinguish these two genotypes are revealed, which may lead to the development of antibody-based drugs for the specific treatment against HEV.